CD1a and bound lipids drive T-cell responses in human skin disease.


Journal

European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201

Informations de publication

Date de publication:
10 2023
Historique:
revised: 03 08 2023
received: 19 03 2023
accepted: 03 08 2023
pmc-release: 01 10 2024
medline: 23 10 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

In addition to serving as the main physical barrier with the outside world, human skin is abundantly infiltrated with resident αβ T cells that respond differently to self, infectious, microbiome, and noxious stimuli.  To study skin T cells during infection and inflammation, experimental biologists track T-cell surface phenotypes and effector functions, which are often interpreted with the untested assumption that MHC proteins and peptide antigens drive measured responses.  However, a broader perspective is that CD1 proteins also activate human T cells, and in skin, Langerhans cells (LCs) are abundant antigen presenting cells that express extremely high levels of CD1a.  The emergence of new experimental tools, including CD1a tetramers carrying endogenous lipids, now show that CD1a-reactive T cells comprise a large population of resident T cells in human skin.  Here, we review studies showing that skin-derived αβ T cells directly recognize CD1a proteins, and certain bound lipids, such as contact dermatitis allergens, trigger T-cell responses. Other natural skin lipids inhibit CD1a-mediated T-cell responses, providing an entry point for the development of therapeutic lipids that block T-cell responses. Increasing evidence points to a distinct role of CD1a in type 2 and 22 T-cell responses, providing new insights into psoriasis, contact dermatitis, and other T-cell-mediated skin diseases.

Identifiants

pubmed: 37539748
doi: 10.1002/eji.202250333
pmc: PMC10592190
mid: NIHMS1923363
doi:

Substances chimiques

Lipids 0
Antigens, CD1 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2250333

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAMS NIH HHS
ID : R01 AR048632
Pays : United States
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2023 Wiley-VCH GmbH.

Références

Eur J Immunol. 2022 Mar;52(3):511-524
pubmed: 34913478
Science. 1996 Oct 4;274(5284):94-6
pubmed: 8810254
J Invest Dermatol. 2012 Jan;132(1):241-4
pubmed: 21900947
J Exp Med. 2015 Feb 9;212(2):149-63
pubmed: 25584012
Immunity. 2005 Feb;22(2):209-19
pubmed: 15723809
Nat Immunol. 2019 Dec;20(12):1644-1655
pubmed: 31636468
J Exp Med. 2020 Mar 2;217(3):
pubmed: 31845972
Eur J Immunol. 1979 Mar;9(3):205-10
pubmed: 376318
Immunity. 2010 Dec 14;33(6):853-62
pubmed: 21167756
Nat Immunol. 2014 Feb;15(2):177-85
pubmed: 24362891
Trends Immunol. 2009 Feb;30(2):67-74
pubmed: 19138566
Nat Immunol. 2016 Oct;17(10):1159-66
pubmed: 27548435
Nat Immunol. 2010 Dec;11(12):1102-9
pubmed: 21037579
Front Immunol. 2022 Jul 07;13:897873
pubmed: 35874748
Nat Commun. 2022 Dec 7;13(1):7535
pubmed: 36477177
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33393500
Sci Transl Med. 2016 Feb 10;8(325):325ra18
pubmed: 26865566
Immunity. 2007 Aug;27(2):203-13
pubmed: 17707129
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1266-75
pubmed: 26884207
Eur J Immunol. 2017 Jul;47(7):1171-1180
pubmed: 28440548
J Exp Med. 2016 Oct 17;213(11):2399-2412
pubmed: 27670592
J Immunol. 1999 Jan 1;162(1):366-71
pubmed: 9886408
Science. 2004 Jan 23;303(5657):527-31
pubmed: 14739458
Sci Immunol. 2017 Dec 22;2(18):
pubmed: 29273672
Sci Immunol. 2023 Jun 8;8(84):eadd9232
pubmed: 37267382
Nat Immunol. 2023 Jan;24(1):110-122
pubmed: 36550321
Nat Immunol. 2003 Aug;4(8):808-15
pubmed: 12833155
Curr Top Microbiol Immunol. 2007;314:113-41
pubmed: 17593659
Sci Immunol. 2021 Jun 25;6(60):
pubmed: 34172588
Sci Immunol. 2020 Jan 3;5(43):
pubmed: 31901073
Nat Immunol. 2009 Aug;10(8):857-63
pubmed: 19578369
Eur J Immunol. 2011 Mar;41(3):602-10
pubmed: 21246542
Nature. 1994 Dec 15;372(6507):691-4
pubmed: 7527500
J Exp Med. 2002 Apr 15;195(8):1013-21
pubmed: 11956292
J Immunol. 2006 Apr 1;176(7):4431-9
pubmed: 16547281
J Immunol. 2013 Nov 1;191(9):4499-503
pubmed: 24089190
Science. 1996 Dec 13;274(5294):1855-9
pubmed: 8943189
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33961028
Eur J Immunol. 2016 Jan;46(1):242-52
pubmed: 26518614
Nat Immunol. 2018 Apr;19(4):397-406
pubmed: 29531339
Nat Immunol. 2015 Mar;16(3):258-66
pubmed: 25642819
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):E4648-57
pubmed: 25298532

Auteurs

Graham S Ogg (GS)

Medical Research Council Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Jamie Rossjohn (J)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff, UK.

Rachael A Clark (RA)

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

D Branch Moody (DB)

Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH